- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
SC dismisses plea seeking CBI probe against 10 pharma cos for selling Remdesivir, Favipiravir without valid license
New Delhi: The Supreme Court on Monday dismissed a plea alleging use of drugs Remdesivir and Favipiravir, without approval, for treatment of Covid-19 and also seeking CBI probe against ten Indian pharmaceutical firms for selling these medicines allegedly in the absence of valid licenses.
A bench, headed by Chief Justice of India D.Y. Chandrachud and comprising Justices P.S. Narasimha and J.B. Pardiwala said these issues cannot be examined by the court and dismissed the plea filed by advocate M.L. Sharma.
In October 2020, the Supreme Court had sought Centre's reply on the plea alleging that Remdesivir and Favipiravir are being used for treatment of Covid-19 without approval.
A bench headed by then Chief Justice S.A. Bobde had issued notice to the Centre on the plea and sought its response in four weeks.
Sharma, petitioner in-person, had then cited the World Health Organisation (WHO) report and argued that nowhere in it were these medicines designated officially as medicines for coronavirus.
The WHO report indicated that Remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon regimens appeared to have little or no effect in the treatment of Covid-19.
In September 2020, the top court had said that there was an approval by the Centre on use of Remdesivir and Favipiravir, as medicines to treat Covid-19.
Sharma also sought registration of an FIR by the CBI against ten Indian pharmaceutical firms for manufacturing and selling these two medicines for treating Covid-19 patients allegedly without valid licences.
In the plea, he had contended that Remdesivir and Favipiravir are antiviral drugs and their efficacy in treatment of Covid patients is still under debate.
Read also: Gilead Sciences Remdesivir gets USFDA nod for young children
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.